Search research articles
Contact Us
Filters
Showing results (11-20 of 59) with videos related to
Page
of 6
Sort By:
Current Hematologic Malignancy Reports
|
April 29, 2010
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
Ronan Swords, Yesid Alvarado, Jorge Cortes, et al.
Drugs
|
October 12, 2007
Treatment of acute lymphoblastic leukaemia : a new era
Effrosyni Apostolidou, Ronan Swords, Yesid Alvarado, et al.
Expert Review of Hematology
|
July 12, 2012
EPHA3 as a novel therapeutic target in the hematological malignancies
Niamh Keane, Ciara Freeman, Ronan Swords, et al.
Leukemia & Lymphoma
|
April 22, 2024
Evaluating targeted therapies in older patients with <i>TP53</i>-mutated AML
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Expert Review of Hematology
|
February 5, 2013
Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia
Niamh Keane, Ciara Freeman, Ronan Swords, et al.
Drug Design, Development and Therapy
|
November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.
Expert Review of Hematology
|
November 19, 2010
Clinical activity of laromustine (Onrigin™) in hematologic malignancies
Yesid Alvarado, Ronan Swords, Kevin R Kelly, et al.
Targeted Oncology
|
April 22, 2009
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Kevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Future Oncology (London, England)
|
May 8, 2013
New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies
Agustin Pimentel, Michel Velez, Luz J Barahona, et al.
Advances in Experimental Medicine and Biology
|
May 14, 2014
The role of inflammation in leukaemia
Francis J Giles, Janusz Krawczyk, Michael O'Dwyer, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 59) with videos related to
Sort By:
Page
of 6
Current Hematologic Malignancy Reports
|
April 29, 2010
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
Ronan Swords, Yesid Alvarado, Jorge Cortes, et al.
Drugs
|
October 12, 2007
Treatment of acute lymphoblastic leukaemia : a new era
Effrosyni Apostolidou, Ronan Swords, Yesid Alvarado, et al.
Expert Review of Hematology
|
July 12, 2012
EPHA3 as a novel therapeutic target in the hematological malignancies
Niamh Keane, Ciara Freeman, Ronan Swords, et al.
Leukemia & Lymphoma
|
April 22, 2024
Evaluating targeted therapies in older patients with <i>TP53</i>-mutated AML
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Expert Review of Hematology
|
February 5, 2013
Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia
Niamh Keane, Ciara Freeman, Ronan Swords, et al.
Drug Design, Development and Therapy
|
November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.
Expert Review of Hematology
|
November 19, 2010
Clinical activity of laromustine (Onrigin™) in hematologic malignancies
Yesid Alvarado, Ronan Swords, Kevin R Kelly, et al.
Targeted Oncology
|
April 22, 2009
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Kevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Future Oncology (London, England)
|
May 8, 2013
New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies
Agustin Pimentel, Michel Velez, Luz J Barahona, et al.
Advances in Experimental Medicine and Biology
|
May 14, 2014
The role of inflammation in leukaemia
Francis J Giles, Janusz Krawczyk, Michael O'Dwyer, et al.
Page
of 6